Comparing Recombinant Interferon and Doxorubicin for Liver Cancer Treatment
Author Information
Author(s): C.-L. Lail, P.-C. Wu, A.S.-F. Lok, H.-J. Lin, H. Ngan, J.Y.-N. Lau, H.-T. Chung, M.M.-T. Ng, E.-K. Yeoh, M. Arnold
Primary Institution: University of Hong Kong, Queen Mary Hospital
Hypothesis
Is recombinant a2 interferon more effective than doxorubicin for treating inoperable hepatocellular carcinoma?
Conclusion
Recombinant a2 interferon is superior to doxorubicin in treating inoperable hepatocellular carcinoma, leading to more tumor regression and fewer serious side effects.
Supporting Evidence
- Patients treated with recombinant interferon had a median survival of 8.3 weeks compared to 4.8 weeks for those on doxorubicin.
- Recombinant interferon induced tumor regression in 22% of patients, with 10% showing over 50% regression.
- Doxorubicin was associated with fatal complications in 25% of patients, while recombinant interferon had a fatality rate of only 3.8%.
Takeaway
This study found that a new treatment called recombinant interferon works better than an older drug called doxorubicin for some patients with liver cancer.
Methodology
Patients were randomized to receive either doxorubicin or recombinant a2 interferon, with assessments of survival, tumor regression, and drug toxicity.
Potential Biases
Potential bias in patient selection and treatment assignment.
Limitations
The study had a small sample size and was limited to patients with specific health criteria.
Participant Demographics
75 Chinese patients with histologically proven inoperable hepatocellular carcinoma.
Statistical Information
P-Value
0.00199
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website